Key Points
- United Therapeutics CEO Martine Rothblatt sold 9,500 shares on July 8 for about $5.26 million at an average price of $553.17, reducing her direct holdings by 19% to 40,513 shares.
- The stock was down slightly in trading, opening at $552.48 and reflecting a modest 0.3% decline, while still trading near the upper end of its 12-month range.
- Analysts remain broadly positive on UTHR, with 10 Buy ratings and 2 Hold ratings, and a consensus target price of $646.00 despite the company’s most recent earnings miss.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $553.17, for a total transaction of $5,255,115.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company's stock, valued at approximately $22,410,576.21. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
United Therapeutics Trading Down 0.3%
Shares of UTHR opened at $552.48 on Friday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The company has a market capitalization of $23.45 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 1.82 and a beta of 0.58. The business's 50 day moving average is $557.18 and its 200 day moving average is $529.32.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analysts' expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.63 EPS. Equities research analysts predict that United Therapeutics Corporation will post 26.63 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on UTHR. Cantor Fitzgerald lifted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Weiss Ratings restated a "buy (b)" rating on shares of United Therapeutics in a report on Thursday, June 11th. Raymond James Financial initiated coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an "outperform" rating and a $700.00 target price on the stock. Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $646.00.
Check Out Our Latest Stock Analysis on United Therapeutics
Hedge Funds Weigh In On United Therapeutics
Several hedge funds have recently added to or reduced their stakes in UTHR. PensionDanmark Pensionsforsikringsaktieselskab boosted its position in shares of United Therapeutics by 7.4% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 11,058 shares of the biotechnology company's stock valued at $5,992,000 after buying an additional 760 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of United Therapeutics by 79.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 84,538 shares of the biotechnology company's stock worth $45,805,000 after acquiring an additional 37,355 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of United Therapeutics by 10.3% during the 2nd quarter. GAMMA Investing LLC now owns 1,769 shares of the biotechnology company's stock worth $958,000 after acquiring an additional 165 shares during the last quarter. Versant Capital Management Inc lifted its stake in shares of United Therapeutics by 93.6% during the 2nd quarter. Versant Capital Management Inc now owns 182 shares of the biotechnology company's stock worth $99,000 after acquiring an additional 88 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its holdings in United Therapeutics by 0.7% during the 1st quarter. Pacer Advisors Inc. now owns 243,545 shares of the biotechnology company's stock valued at $144,417,000 after acquiring an additional 1,673 shares during the period. 94.08% of the stock is currently owned by institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
